Tag Archives: healthcare

Worldwide Orphan Drug Market to Grow to $127 Billion by 2018

Infographic

The 2013 Orphan Drug Report from Evaluate, which launched today at the 2013 BIO international Convention, sheds light on the market dynamics of orphan drugs — pharmaceutical products aimed at rare diseases or disorders — projecting that sales will experience a compound annual growth rate of 7.4 percent between 2012 and 2018, nearly double that of the prescription drug market, excluding generics.  The report based on EvaluatePharma® data found that the worldwide orphan drug market Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Expanding Access to Orphan Drugs

Orphan Drugs

At present many orphan diseases do not have any licensed treatments, and for those conditions where there is a therapy, it is often the only therapy in the class that is available. However, this is not always the case. In the field of blood-plasma proteins, therapies to treat hemophilia, alpha-1 deficiency and primary immune deficiencies have multiple innovator versions in a therapeutic class. Often one product in the class has received an orphan designation and Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Our Health Care Ecosystem

Meekers

There are currently 907 drugs and vaccines targeting more than 100 diseases in development by U.S. biopharmaceutical companies. It is the first step on a path toward bringing much needed treatments to patients. However, with the current focus on the cost of health care, regulatory approval is not the final hurdle. Increasingly, the ability of patients to access new therapies is determined by those who pay for the treatments. Skyrocketing development costs, concerns about the Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Approving Drugs for Alzheimer’s Disease

Russ Katz

BIOtechNOW delves into the current state of Alzheimer’s disease research with today’s feature on regulatory challenges. Tomorrow, we cover the first Alzheimer’s prevention trial, and on Wednesday, we will explore the societal and economic impact of this devastating disease. The therapies currently approved for Alzheimer’s disease work by treating the patients’ symptoms, improving their cognitive and overall functions. Increasingly, however, experts are intent on slowing or halting the disease process—before it has ravaged patients’ brains. In February, the U.S. Food Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Patients are the Missing Link in R&D

Elias Zerhouni

An architect does not wait until construction begins to show clients a blueprint. Neither does a caterer prepare a banquet meal without consulting first with the host. In biopharmaceutical science, however, for too long we have developed medicines without engaging patients early on and throughout the process. If scientific innovation is to truly be innovative, we need to be more interested in the people our products will help. We need to rethink innovation. The model we’ve used in healthcare Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,